Physician profile
Samir Dabbous
NPI 1538195664
$6,341.33
in general payments reported to CMS, 2019-2025
26 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,332 · 2020: $249 · 2021: $398 · 2022: $545 · 2023: $762 · 2024: $1,496 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,128.27 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $567.79 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $406.89 | 2020-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $390.53 | 2022-2025 | Lifevest |
| Abiomed | $305.17 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.74 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $271.49 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $258.28 | 2020-2022 | |
| Heartflow, INC. | $235.38 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $232.51 | 2019-2024 | Farxiga, Wainua |
| Abbott Laboratories | $178.27 | 2023-2024 | Coroflow, Cardiomems |
| Cardiva Medical, INC. | $175.98 | 2023-2025 | Savvywire, Cardiva Vascade 6/7f Vcs |
| Chiesi USA, INC. | $151.49 | 2021-2025 | Kengreal, Juxtapid, Cleviprex |
| Novartis Pharmaceuticals Corporation | $126.19 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $121.37 | 2019-2023 | Xarelto |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115.73 | 2024-2025 | Wegovy |
| Pfizer INC. | $85.01 | 2019-2023 | |
| Medtronic, INC. | $73.02 | 2024 | V-Loc 180 |
| Sanofi-Aventis U.S. LLC | $69.70 | 2019-2023 | |
| Cardinal Health 200 LLC | $35.30 | 2020-2021 | |
| Amarin Pharma, INC. | $30.68 | 2021 | |
| Zoll Circulation INC | $30.23 | 2023-2024 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Esperion Therapeutics, INC. | $20.95 | 2020 | |
| Cordis US Corp. | $19.37 | 2024 | Mynxgrip |
| Teleflex LLC | $18.50 | 2020 | |
| Irhythm Technologies, INC. | $17.49 | 2024 | Zio At Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Dabbous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.